C 
China Resources Boya Bio pharmaceutical Group Co 300294.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
14.02
-1.61%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥2.05bn
FY2016FY2025
Net income
CN¥112.7m
FY2016FY2025
Free cash flow
−CN¥418.6m
FY2016FY2025
Shareholders' equity
CN¥7.44bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥2.05bn | CN¥1.73bn | CN¥2.65bn | CN¥2.76bn | CN¥2.65bn | CN¥2.51bn | CN¥2.91bn | CN¥2.39bn | CN¥1.39bn | CN¥946.6m |
| Gross profit | CN¥936.9m | CN¥1.12bn | CN¥1.39bn | CN¥1.50bn | CN¥1.46bn | CN¥1.46bn | CN¥1.78bn | CN¥1.52bn | CN¥969.3m | CN¥596.7m |
| Research and development | CN¥50.7m | CN¥71.3m | CN¥67.7m | CN¥49.6m | CN¥59.3m | CN¥90.7m | CN¥92.8m | CN¥45.1m | CN¥34.5m | CN¥42.4m |
| Operating income | CN¥269.7m | CN¥477.3m | CN¥355.2m | CN¥532.2m | CN¥443.1m | CN¥331.5m | CN¥522.7m | CN¥554.1m | CN¥429.4m | CN¥325.6m |
| Net income | CN¥112.7m | CN¥397.0m | CN¥237.5m | CN¥432.2m | CN¥344.5m | CN¥260.1m | CN¥426.1m | CN¥469.2m | CN¥356.6m | CN¥272.0m |
| Diluted earnings per share | 0.22 | 0.79 | 0.47 | 0.86 | 0.68 | 0.59 | 1.03 | 1.10 | 0.88 | 0.68 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥8.63bn | CN¥8.40bn | CN¥7.83bn | CN¥8.03bn | CN¥7.62bn | CN¥5.16bn | CN¥5.26bn | CN¥5.07bn | CN¥3.67bn | CN¥2.42bn |
| Cash and short-term investments | CN¥3.23bn | CN¥3.50bn | CN¥5.32bn | CN¥4.73bn | CN¥4.28bn | CN¥753.9m | CN¥568.7m | CN¥1.19bn | CN¥502.5m | CN¥422.1m |
| Total liabilities | CN¥1.16bn | CN¥913.4m | CN¥508.1m | CN¥748.3m | CN¥701.3m | CN¥966.1m | CN¥1.27bn | CN¥1.30bn | CN¥1.19bn | CN¥287.3m |
| Debt | CN¥332.9m | CN¥7.2m | CN¥23.5m | CN¥35.4m | CN¥35.6m | CN¥330.4m | CN¥623.4m | CN¥606.5m | CN¥527.1m | CN¥22.1m |
| Shareholders' equity | CN¥7.44bn | CN¥7.49bn | CN¥7.32bn | CN¥7.19bn | CN¥6.83bn | CN¥4.11bn | CN¥3.91bn | CN¥3.70bn | CN¥2.43bn | CN¥2.09bn |
| Shares outstanding | 504m | 504m | 504m | 504m | 504m | 438m | 414m | 427m | 405m | 398m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥116.7m | CN¥299.8m | CN¥641.7m | CN¥596.4m | CN¥1.35bn | CN¥718.6m | −CN¥114.5m | CN¥34.9m | −CN¥23.8m | CN¥198.8m |
| Capital spending | −CN¥535.3m | −CN¥197.8m | −CN¥87.5m | −CN¥138.4m | −CN¥68.1m | −CN¥142.5m | −CN¥88.6m | −CN¥113.9m | −CN¥237.8m | −CN¥300.1m |
| Free cash flow | −CN¥418.6m | CN¥102.0m | CN¥554.2m | CN¥458.0m | CN¥1.28bn | CN¥576.1m | −CN¥203.1m | −CN¥79.0m | −CN¥261.6m | −CN¥101.3m |
| Dividends paid | −CN¥156.3m | −CN¥232.4m | −CN¥134.9m | −CN¥75.6m | −CN¥27.7m | −CN¥63.9m | −CN¥65.0m | −CN¥101.7m | −CN¥39.6m | −CN¥55.1m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥322.4m | CN¥321.1m | CN¥585.2m | CN¥466.2m | CN¥471.9m | CN¥535.9m | CN¥489.8m | CN¥349.4m |
| Gross profit | CN¥135.9m | CN¥148.6m | CN¥208.4m | CN¥264.7m | CN¥245.6m | CN¥288.3m | CN¥288.9m | CN¥229.9m |
| Operating income | −CN¥1.6m | CN¥18.5m | −CN¥259.9m | CN¥39.0m | CN¥100.3m | CN¥162.4m | −CN¥3.0m | CN¥113.7m |
| Net income | CN¥21.0m | CN¥30.2m | −CN¥230.3m | CN¥117.6m | CN¥85.9m | CN¥139.5m | −CN¥15.7m | CN¥96.7m |
| Diluted earnings per share | 0.04 | 0.06 | -0.46 | 0.23 | 0.17 | 0.28 | -0.03 | 0.19 |
| Cash from operations | — | — | CN¥36.0m | CN¥43.0m | CN¥49.0m | −CN¥21.0m | — | CN¥62.0m |
| Capital spending | −CN¥95.0m | −CN¥187.0m | −CN¥122.0m | −CN¥131.0m | −CN¥161.0m | −CN¥119.0m | −CN¥78.0m | −CN¥67.0m |
| Free cash flow | — | — | −CN¥86.0m | −CN¥88.0m | −CN¥112.0m | −CN¥140.0m | — | −CN¥5.0m |
| Total assets | CN¥8.28bn | CN¥8.41bn | CN¥8.63bn | CN¥8.73bn | CN¥8.68bn | CN¥8.48bn | CN¥8.40bn | CN¥8.16bn |
| Cash and short-term investments | — | — | CN¥3.23bn | CN¥3.12bn | CN¥3.17bn | CN¥3.35bn | CN¥3.50bn | CN¥5.24bn |
| Debt | CN¥58.3m | CN¥58.3m | CN¥320.2m | CN¥259.9m | CN¥206.0m | CN¥230.9m | — | — |
| Shareholders' equity | CN¥7.44bn | CN¥7.46bn | CN¥7.44bn | CN¥7.67bn | CN¥7.63bn | CN¥7.63bn | CN¥7.49bn | CN¥7.58bn |
Financial ratios
Data as of 4 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 45.7% | 64.5% | 52.5% | 54.5% | 55.2% | 58.0% | — | — |
| Operating margin | 13.2% | 27.5% | 13.4% | 19.3% | 16.7% | 13.2% | — | — |
| Net margin | 5.5% | 22.9% | 9.0% | 15.7% | 13.0% | 10.3% | — | — |
| Return on equity | 1.5% | 5.3% | 3.2% | 6.0% | 5.0% | 6.3% | — | — |
| Return on assets | 1.3% | 4.7% | 3.0% | 5.4% | 4.5% | 5.0% | — | — |
| Free cash flow yield | 8.7% | 6.6% | 9.7% | 9.8% | 18.8% | 13.2% | — | — |
| Revenue growth | 18.2% | -34.6% | -3.9% | 4.1% | 5.5% | -13.6% | — | — |
| Earnings growth | -71.6% | 67.2% | -45.1% | 25.4% | 32.5% | -39.0% | — | — |
| Current ratio | 5.06x | 6.74x | 14.08x | 8.61x | 8.95x | 3.36x | — | — |
| Debt to equity | 0.04x | — | 0.00x | — | 0.00x | 0.07x | 0.16x | 0.15x |
| Equity ratio | 86.2% | 89.1% | 93.5% | 89.4% | 89.6% | 79.6% | — | — |
| Interest coverage | 172.34x | 437.99x | 443.73x | 577.16x | 42.08x | 15.15x | — | — |
| R&D as a share of sales | 2.5% | 4.1% | 2.6% | 1.8% | 2.2% | 3.6% | — | — |
| Buybacks as a share of market value | 0.0% | 0.0% | 0.0% | 0.0% | -15.1% | -5.9% | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -9.4% | -4.0% | 14.2% |
| Operating income | -20.3% | -4.0% | 6.3% |
| Net income | -36.1% | -15.4% | -2.9% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 54.3% | 53.9% | 54.8% | 58.1% |
| Operating margin | 19.7% | 17.8% | 16.8% | 19.5% |
| Net margin | 13.5% | 12.8% | 12.4% | 15.4% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 101.1 | 38.5 | 71.5 | 42.6 | 56.1 | 56.5 | 30.3 | 24.6 | 34.0 | 54.9 |
| Price to sales | 5.6 | 8.8 | 6.4 | 6.7 | 7.3 | 5.8 | 4.4 | 4.8 | 8.7 | 15.8 |
Dividends and splits
Per share, in the currency the company pays
Paid for 14 years. Last went ex-dividend on 20 May 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.073 | 0.31 | 0.46 | 0.20 | 0.15 | 0.065 | 0.15 | 0.153 |
- 3-for-2 split · 26 May 2017
- 2-for-1 split · 18 Sept 2015
- 3-for-2 split · 7 Apr 2015
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.